What is Leucine?
Founded in 2019, Leucine provides a specialized no-code software suite designed to streamline complex manufacturing, quality assurance, and quality control processes. By enabling pharmaceutical teams to implement compliance-by-design across their workflows—from initial material receipt to final batch release—the company addresses the persistent challenges of regulatory adherence in a high-stakes industry. Leucine's platform is currently utilized by manufacturing facilities worldwide to drive sustainability and operational excellence, effectively replacing legacy paper-based systems with a modern, digital-first architecture that ensures continuous audit readiness.
How much funding has Leucine raised?
Leucine has raised a total of $7M across 1 funding round:
Series A
$7M
Series A (2023): $7M with participation from Ecolab
Key Investors in Leucine
Ecolab
Ecolab Inc. is a global leader in water, hygiene, and infection prevention solutions, providing critical contamination control and cleaning technologies to the pharmaceutical and life sciences industries.
What's next for Leucine?
The infusion of capital from this major strategic investment will likely be directed toward expanding Leucine's engineering capabilities and deepening its market penetration within the global life sciences sector. As pharmaceutical manufacturers face increasing pressure to modernize their production environments, Leucine's no-code approach offers a scalable pathway to digital transformation. Future growth initiatives are expected to focus on enhancing the platform's integration features and broadening its utility across diverse regulatory frameworks, ensuring that Leucine remains at the forefront of the pharmaceutical manufacturing technology landscape. The company is now poised to transition from its current scaling phase into a broader market leadership position, leveraging its unique value proposition to capture a larger share of the enterprise compliance software market.
See full Leucine company page
